Rait AS - Search Results

1

Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors.

Gunaratne PH, Pan Y, Rao AK, Lin C, Hernandez-Herrera A, Liang K, Rait AS, Venkatanarayan A, Benham AL, Rubab F, Kim SS, Rajapakshe K, Chan CK, Mangala LS, Lopez-Berestein G, Sood AK, Rowat AC, Coarfa C, Pirollo KF, Flores ER, Chang EH. Gunaratne PH, et al. Among authors: rait as. Cancer. 2019 Jul 15;125(14):2409-2422. doi: 10.1002/cncr.32053. Epub 2019 Apr 23. Cancer. 2019. PMID: 31012964 Free PMC article.

2

Evidence supporting a signal transduction pathway leading to the radiation-resistant phenotype in human tumor cells.

Pirollo KF, Hao Z, Rait A, Ho CW, Chang EH. Pirollo KF, et al. Biochem Biophys Res Commun. 1997 Jan 3;230(1):196-201. doi: 10.1006/bbrc.1996.5922. Biochem Biophys Res Commun. 1997. PMID: 9020045 Free article.

3

p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy.

Pirollo KF, Hao Z, Rait A, Jang YJ, Fee WE Jr, Ryan P, Chiang Y, Chang EH. Pirollo KF, et al. Oncogene. 1997 Apr 10;14(14):1735-46. doi: 10.1038/sj.onc.1201116. Oncogene. 1997. PMID: 9135075

4

Restoration of the G1 checkpoint and the apoptotic pathway mediated by wild-type p53 sensitizes squamous cell carcinoma of the head and neck to radiotherapy.

Chang EH, Jang YJ, Hao Z, Murphy G, Rait A, Fee WE Jr, Sussman HH, Ryan P, Chiang Y, Pirollo KF. Chang EH, et al. Arch Otolaryngol Head Neck Surg. 1997 May;123(5):507-12. doi: 10.1001/archotol.1997.01900050055007. Arch Otolaryngol Head Neck Surg. 1997. PMID: 9158398

5

Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts.

Xu L, Pirollo KF, Tang WH, Rait A, Chang EH. Xu L, et al. Hum Gene Ther. 1999 Dec 10;10(18):2941-52. doi: 10.1089/10430349950016357. Hum Gene Ther. 1999. PMID: 10609655

6

3'-End conjugates of minimally phosphorothioate-protected oligonucleotides with 1-O-hexadecylglycerol: synthesis and anti-ras activity in radiation-resistant cells.

Rait A, Pirollo K, Will DW, Peyman A, Rait V, Uhlmann E, Chang EH. Rait A, et al. Bioconjug Chem. 2000 Mar-Apr;11(2):153-60. doi: 10.1021/bc990106n. Bioconjug Chem. 2000. PMID: 10725091

7

Inhibition of Ras p21 synthesis by antisense undecamers with uniform and specifically arranged phosphorothioate linkages.

Rait A, Uhlmann E, Peyman A, Will DW, Chang EH. Rait A, et al. Anticancer Drugs. 2000 Mar;11(3):181-91. doi: 10.1097/00001813-200003000-00006. Anticancer Drugs. 2000. PMID: 10831277

8

Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer.

Rait AS, Pirollo KF, Rait V, Krygier JE, Xiang L, Chang EH. Rait AS, et al. Cancer Gene Ther. 2001 Oct;8(10):728-39. doi: 10.1038/sj.cgt.7700359. Cancer Gene Ther. 2001. PMID: 11687896

9

Downmodulation of bFGF-binding protein expression following restoration of p53 function.

Sherif ZA, Nakai S, Pirollo KF, Rait A, Chang EH. Sherif ZA, et al. Cancer Gene Ther. 2001 Oct;8(10):771-82. doi: 10.1038/sj.cgt.7700361. Cancer Gene Ther. 2001. PMID: 11687900

10

Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv.

Xu L, Tang WH, Huang CC, Alexander W, Xiang LM, Pirollo KF, Rait A, Chang EH. Xu L, et al. Mol Med. 2001 Oct;7(10):723-34. Mol Med. 2001. PMID: 11713371 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

46 results

Search Page